To date, studies of cancer-associated SF3B1 mutations have been carried out in blood cancer patient cells (MDS, AML, CLL), blood cells from mouse models, blood cancer cell lines (e.g., NALM and K562), or non-blood transformed cell lines (e.g., HeLa and HEK293 cells) [23,26–33]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.